Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR)-Reference-Cited by-同舟云学术

Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR)

Published:2021 Issue:3 Volume:61 Page:135-144
ISSN:1346-4280
Container-title:Journal of Clinical and Experimental Hematopathology
language:en
Short-container-title:J Clin Exp Hematopathol

Author:

Izutsu Koji¹,Suzumiya Junji²,Takizawa Jun³,Fukase Kenjiro⁴,Nakamura Maki⁴,Jinushi Masahisa⁴,Nagai Hirokazu⁵

Affiliation:

1. Department of Hematology, National Cancer Center Hospital, Tokyo, Japan,

2. Innovative Cancer Center, Shimane University Hospital, Izumo, Japan,

3. Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan,

4. AstraZeneca K.K., Osaka, Japan,

5. Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan

Publisher

Japanese Society for Lymphoreticular Tissue Research

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jslrt/61/3/61_20056/_pdf

Reference14 articles.

1. 1 Klener P. Advances in molecular biology and targeted therapy of mantle cell lymphoma. Int J Mol Sci. 2019; 20: 4417.

2. 2 . The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000; 50: 696-702.

3. 3 Japanese Society of Hematology. JSH practical guidelines for hematological malignancies, 2018, Chapter IV Lymphoma. II Lymphoma. 4 Mantle cell lymphoma. Available at: http://www.jshem.or.jp/gui-hemali/2_4.html. Accessed March 9, 2020 [in Japanese].

4. 4 Maruyama D, Nagai H, Fukuhara N et al. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. J Clin Exp Hematop. 2019; 59: 98-100.

5. 5 Wang ML, Blum KA, Martin P et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015; 126: 739-745.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance;International Journal of Hematology;2024-01-09

2. Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan;Journal of Clinical and Experimental Hematopathology;2024

3. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma;International Journal of Clinical Oncology;2023-12-29

4. Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma: The Swedish MCLcomplete Project;HemaSphere;2023-07-28

5. Real‐world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis;Cancer Medicine;2023-05-06